| Development update
Eli Lilly has registered a phase 1 trial of LY4247147 on ClinicalTrials.gov, NCT07915245. The Atlas checked the record on November 9, 2026. It lists the study as not yet recruiting. The trial is randomized and placebo-controlled, with single and multiple ascending doses, and plans to enroll 108 people.
Participants are adults aged 18 to 65 (21 to 65 in Singapore) with obesity or overweight who are otherwise healthy, with a BMI of at least 27 and a stable weight for three months. The study has three parts. Parts A and C last about 30 weeks and include about 8 nights in a clinical research unit. Part B lasts about 39 weeks, with up to 3 stays of about 9 nights.
The primary outcomes are treatment-related adverse events and serious adverse events. Secondary outcomes describe how the body handles the drug: peak concentration (Cmax), time to peak (Tmax) and total exposure (AUC). The record gives a start in November 2026 and primary completion in October 2028. The sites are ICON in Lenexa, Kansas, ICON in Salt Lake City, Utah, and the Lilly Centre for Clinical Pharmacology in Singapore.
Worth knowing: The record does not say what kind of medicine LY4247147 is, how it is given or which doses will be tested, and the Atlas does not guess. A phase 1 study is mainly a safety and dosing study. LY numbers are Lilly's internal codes.
Related: Lilly LY numbers explained | Pipeline | Lilly tracker | Bimagrumab heart failure trial
Source: ClinicalTrials.gov, LY4247147 phase 1 (NCT07915245) Trial registry.